GlassScriptPhysician profile
Patricia M Ryan
NPI 1790740033
$4,262.77
in general payments reported to CMS, 2019-2025
40 companies · $764 in 2025
The $764 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $564 · 2020: $172 · 2021: $765 · 2022: $650 · 2023: $706 · 2024: $642 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,112.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,111.99 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $604.09 | 2019-2025 | |
| Novo Nordisk INC | $397.76 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $207.82 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $171.65 | 2019-2024 | Repatha, Otezla, Evenity |
| Amarin Pharma, INC. | $158.97 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $147.96 | 2019-2025 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $135.63 | 2019-2025 | Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $126.37 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $117.18 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.50 | 2020-2021 | |
| Boston Scientific Corporation | $81.29 | 2023-2025 | Watchman Flx, Watchman |
| Biohaven Pharmaceutical Holding Company LTD. | $78.09 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.78 | 2022-2023 | |
| Shield Therapeutics INC | $70.02 | 2025 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.